Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
6 clinical trials · Condition
◉ Watch Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
| Record | Firm | Date |
|---|---|---|
| Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study (NCT04900623) | Jonathan Schoenfeld, MD, MPH | 2021-07-02 |
| Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries (NCT04489212) | Mayo Clinic | 2020-10-06 |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NCT03952585) | National Cancer Institute (NCI) | 2019-10-09 |
| Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (NCT03799445) | M.D. Anderson Cancer Center | 2019-07-25 |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer (NCT03010150) | M.D. Anderson Cancer Center | 2016-12-29 |
Track Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 automatically
Every clearance here is in the API, with alerts when new ones post.